MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA
MediPharm Labs scrapes to adjusted EBITDA profitability in Q1 2026, but a veteran affairs reimbursement cut looms large over its direct-to-patient business.
The most recent news from May 13, 2026, reports MediPharm Labs’ Q1 2026 financial results. The company achieved positive adjusted EBITDA of $0.1 million, a swing from a negative $0.1 million in Q4 2025. Quarterly revenue was approximately $9 million with a gross margin of 37% (40.2% adjusted). Operating expenses were reduced by 28% sequentially ($1.6 million) due to restructuring. International medical revenue represented 51% of the total at $4.6 million, propped up by 14% sequential growth in Germany. The company ended the quarter with $9.9 million in cash and is virtually debt-free. Operationally, MediPharm completed its first shipment to New Zealand and secured new purchase agreements in France and Brazil.
The achievement of positive adjusted EBITDA is a symbolic milestone for a company that has long been loss-making, but it must be assessed in context. First, the $0.1 million figure is razor-thin, and it comes after a quarter of significant cost-cutting, including restructuring to achieve $1 million in annualized savings. This indicates profitability is currently a function of expense reduction rather than robust revenue growth. Quarterly revenue of ~$9 million is actually a sequential decline from Q4 2025's $11.1 million, though the Q4 figure may have been seasonally elevated.
The most critical piece of context comes from the FY2025 earnings conference call transcript summary. Management disclosed a major headwind: a Veterans Affairs Canada (VAC) reimbursement cut from $8.50/g to $6.00/g effective April 1, 2026. This is expected to negatively impact direct-to-patient revenue starting in Q2 2026—the very next quarter. This is a material, known risk that directly threatens the sustainability of the company’s Canadian medical revenue stream and its newly achieved EBITDA breakeven status. Therefore, Q1’s positive EBITDA is heavily overshadowed by this imminent and unquantified earnings drag. The news is positive in isolation but lacks the power to change the investment thesis given the VAC risk profile.
MediPharm Labs is a pharmaceutical company specializing in the production of GMP-certified cannabis products for medical and adult-use markets. Its flagship operation is a purpose-built, EU-GMP certified extraction and processing facility in Napanee, Ontario, which also holds a U.S. FDA site registration and a Health Canada Drug Establishment License. The company does not have a single 'flagship project' like a mining asset; its core value proposition is its regulatory-advantaged manufacturing platform designed to serve highly regulated international medical markets (Germany, Australia, Brazil, France, UK, New Zealand) with pharmaceutical-grade cannabinoids, including oils, tinctures, and a proprietary metered-dose inhaler. Following the 2023 acquisition of VIVO Cannabis, the company also operates direct-to-patient medical channels in Canada and Australia through brands like Beacon Medical.